Endpoints News
Partners Merck and Gilead report HIV trial win and lung cancer loss Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M Tue W Th F
9 June, 2026
The Endpoints 100: Despite all the turmoil, biotech is having a moment
A year ago, biotech was in its bleakest stretch in a decade. Now IPOs are rebounding and China deals are heating up. John Carroll and a panel of industry leaders dig into the latest Endpoints 100 results and uncover what’s next for the sector.
presented by McKesson
De­liv­er­ing ex­cel­lence, close to home: Build­ing the in­fra­struc­ture for mod­ern com­mu­ni­ty on­col­o­gy
spotlight
top stories
1. Who pays the best (and worst) in biopharma? A look at typical employee salaries
2. Trodelvy misses again in lung cancer, but Gilead and Merck have an HIV success to soften the blow
3.
news briefing
Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drug
4. GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B
5. WuXi AppTec added to Pentagon's list of companies linked to Chinese military 
6. AstraZeneca's obesity pill matches rivals in Phase 2, anchoring $5B franchise push
7. City Therapeutics gets $99M to gather data on three RNAi medicines
8. Incyte's Meury, now a buyer, sees $2B Vega deal as a step in blood treatments beyond Jakafi
Post-Hoc Live
• 
Karen Weintraub
.

Andrew Dunn’s series on industry pay continues with a look at median pay packages for workers. They’re rising, but still a fraction of what top execs bring home.
.
Karen Weintraub
Deputy Editor, Endpoints News
1
by Andrew Dunn

The typ­i­cal work­er in bio­phar­ma made $116,648 in 2025, ac­cord­ing to an End­points News pay analy­sis, earn­ing about 30% more than the typ­i­cal em­ploy­ee of...

Read full story
2
by Ayisha Sharma

Part­ners Gilead Sci­ences and Mer­ck have re­port­ed a hit and a miss for their Phase 3 HIV and lung can­cer pro­grams, re­spec­tive­ly, but in­vestors were...

Read full story
News Briefing: Quick hits from the biopharma web
3
by ENDPOINTS

Plus news about Para­bilis Med­i­cines, RA Cap­i­tal, Tan­go Ther­a­peu­tics, Ideaya Bio­sciences, Bavar­i­an Nordic and Carte­sian Ther­a­peu­tics

💸 Lil­ly’s $1B Alzheimer’s deal: The In­di­anapo­lis drug­mak­er will...

Read full story
LGBTQ+ LEADERSHIP IN 2026
LGBTQ+ diversity drives innovation in biopharma — but transgender and non-binary professionals face rising challenges. Endpoints is going live with our fourth annual special report celebrating the honorees giving voice and visibility while forging ahead across life sciences. Join us.
4
by Kyle LaHucik

GSK is mak­ing one of the largest biotech ac­qui­si­tions in its his­to­ry to gain ac­cess to two ex­per­i­men­tal lung can­cer med­i­cines that are due for...

Read full story
5